A randomized, open-label, crossover, prospective study to investigate utility of a new 24-hour application of transdermal fentanyl patch compared to 72-hour application of transdermal fentanyl patch.

A randomized, open-label, crossover, prospective study to investigate utility of a new 24-hour application of transdermal fentanyl patch compared to 72-hour application of transdermal fentanyl patch. - A randomized, open-label, crossover, prospective study to investigate utility of a new 24-hour application of transdermal fentanyl patch compared to 72-hour application of transdermal fentanyl patch.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004231

Enrollment

Registered

2010-09-21

Start date

2010-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Interventions

1.Fentos Tape 2.Durotep MT Patch Duration of treatment periods:9 days 1.Durotep MT Patch 2.Fentos Tape Duration of treatment periods:9 days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.In-patient of Kitasato institute Hospital 2.Patient who have moderate or severe cancer-related pain 3.Patient who treated with strong opioids for pain management and score change of his/her face pain scale within 1 4.patient who is judged to change to transdermal fentanyl patch from other opioids 5.Patients who are provided informed, written consent for participation

Exclusion criteria

Exclusion criteria: 1.Patient who have hypersensitivity to opioids 2.Patient who have history of opioid abuse 3.Patient who have skin disease (eczema or psoriasis) on the upper arms, flat surface of the upper torso or crural area 4.A body temperature higher than 40 degrees 5.Preganat or nursing patients and patients who may be pregnant 6.After application of fentanyl patch within two days, patient who is treated by opioid receptor antagonists such as pentazocine and buprenorphine or will be treated 7.Surgery in the preceding 7 days or scheduled 8.Patient under 20 years old 9.Patient who have a life expectancy of less than 1 month 10.Patient who judges that the primary physician is inappropriate

Design outcomes

Primary

Measure	Time frame
1.Pain intensity daily 2.Adverse events daily 3.Result of questionnaire investigation about utility of each transdermal fentanyl patch	—

Countries

Japan

Contacts

Public Contactmasatoshi saito

Kitasato Institute Hospital Department of Pharmacy

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026